Depression - Novel therapies key to market penetration

With the global antidepressant market valued at $16.6 billion in 2002, drugs for the treatment of depression have historically provided huge returns on investment. However, several of the leading brands are expecting patent expiries over the next five years. New strategies are needed to prevent a decline in the antidepressant market. 

Scope

Detailed coverage of the patient potential, unmet needs, and clinical trial design of antidepressants across the seven major markets 

Overview of the drugs in preregistration, Phase III, II, I and preclinical development, with in-depth profiles of Organon and Dov Pharmaceutical 

Profiles of compounds undergoing development for depression, with sales forecasts to 2011, and insight into innovative early stage products 

Evaluation of key clinical trials in the treatment of depression, with revenue forecasts to 2011 

Report Highlights

Duloxetine, Eli Lilly’s follow-up compound to Prozac, is set to become the next drug to enter the antidepressant market. However, convincing physicians that it is superior to Wyeth’s Effexor may prove challenging. Lilly needs to position duloxetine as an alternative first-line therapy to selective serotonin reuptake inhibitors (SSRIs). 

Merck’s NK1 receptor antagonist, aprepitant, is expected to be the first drug from another completely new class of antidepressants to hit the market. Its launch in 2006 will precipitate an influx of similar compounds to the market, presenting a major threat to the leading position of first-line therapy SSRIs. 

Reasons to Purchase

Understand the depression market unmet needs to devise market-penetrating strategies 

Analyze the competitive environment at the time of product launch 

Identify in-licensing and co-promotional opportunities 

Publisher: Datamonitor CNS Central Nervous System Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_CNS.html#a88